Patents Assigned to GTx, Inc.
-
Patent number: 9051267Abstract: The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.Type: GrantFiled: October 1, 2013Date of Patent: June 9, 2015Assignee: GTX, INC.Inventors: James T. Dalton, Mitchell S. Steiner, Jeetendra Eswaraka
-
Patent number: 9029408Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.Type: GrantFiled: October 9, 2013Date of Patent: May 12, 2015Assignees: GTx, Inc., University of Tennessee Research FoundationInventors: Duane D. Miller, Wei Li, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn
-
Publication number: 20140350102Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.Type: ApplicationFiled: June 2, 2014Publication date: November 27, 2014Applicant: GTx, Inc.Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
-
Patent number: 8822513Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.Type: GrantFiled: August 24, 2011Date of Patent: September 2, 2014Assignees: GTX, Inc., University of Tennessee Research FoundationInventors: Yan Lu, Chien-Ming Li, Zhao Wang, Jianjun Chen, Wei Li, James T. Dalton, Duane D. Miller, Charles Duke, Sunjoo Ahn
-
Publication number: 20140228755Abstract: Novel fluid delivery systems are disclosed to improve the delivery of bio-compatible fluids to a patient. The systems can include a housing having a bladder pressurized by a pressurization unit so that fluid flow rate can be controlled, changed and/or monitored. The systems can also include a scale and/or a flow control unit.Type: ApplicationFiled: October 8, 2013Publication date: August 14, 2014Applicant: Athena GTX, Inc.Inventors: Mark I. Darrah, Allen E. Brandenburg
-
Publication number: 20140213623Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.Type: ApplicationFiled: October 9, 2013Publication date: July 31, 2014Applicants: GTx, Inc., University of Tennessee Research FoundationInventors: Duane D. Miller, Li Wei, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn
-
Patent number: 8791158Abstract: The present invention includes methods for treating Meibomian gland dysfunctions. The invention also includes methods for improving tear lipid composition, for treating abnormal Meibomian gland secretion and for normalizing Meibomian gland secretions.Type: GrantFiled: January 11, 2011Date of Patent: July 29, 2014Assignee: GTX, Inc.Inventors: James T. Dalton, Jeetendra Eswaraka
-
Publication number: 20140171468Abstract: The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.Type: ApplicationFiled: October 1, 2013Publication date: June 19, 2014Applicant: GTX, INC.Inventors: James T. Dalton, Mitchell S. Steiner, Jeetendra Eswaraka
-
Publication number: 20140080905Abstract: This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject.Type: ApplicationFiled: July 29, 2013Publication date: March 20, 2014Applicant: GTx, Inc.Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
-
Patent number: 8637706Abstract: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.Type: GrantFiled: January 31, 2012Date of Patent: January 28, 2014Assignee: Gtx, Inc.Inventors: James T. Dalton, Christina Barrett, Duane D. Miller, Seoung-Soo Hong, Yali He, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
-
Patent number: 8563606Abstract: The present invention relates to solid forms of (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.Type: GrantFiled: June 5, 2011Date of Patent: October 22, 2013Assignee: GTx, Inc.Inventors: James T. Dalton, David A. Dickason, Seoung-Soo Hong, Thomas G. Bird, Tai Ahn
-
Patent number: 8546451Abstract: The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.Type: GrantFiled: February 23, 2010Date of Patent: October 1, 2013Assignee: GTx, Inc.Inventors: James T. Dalton, Mitchell S. Steiner, Jeetendra Eswaraka
-
Publication number: 20130197049Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.Type: ApplicationFiled: November 14, 2012Publication date: August 1, 2013Applicants: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTx, Inc.Inventors: GTx, Inc., University Of Tennessee Research Foundation
-
Publication number: 20130150403Abstract: The present application relates to methods of treating, preventing, delaying the onset of, reducing the incidence of, or reducing the severity of hypertension and of a condition associated with cardiovascular diseaseType: ApplicationFiled: October 15, 2012Publication date: June 13, 2013Applicants: VA Long Beach Healthcare System, GTx, Inc.Inventors: GTx, Inc., VA Long Beach Healthcare System
-
Publication number: 20130122085Abstract: This invention provides a pharmaceutical composition comprising Compound I-V, including inter alia solid dosage forms of powder-filled capsule formulations, liquid-filled softgel capsules (softgels), tablets, and sustained release dosage forms, and uses thereof in treating a variety of diseases or conditions in a subject, for example, treating a muscle wasting disease and/or disorder, a bone related disease and/or disorder, metabolic syndrome, diabetes and associated diseases, and others.Type: ApplicationFiled: November 1, 2012Publication date: May 16, 2013Applicant: GTx, Inc.Inventor: GTx, Inc.
-
Patent number: 8158828Abstract: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.Type: GrantFiled: April 16, 2007Date of Patent: April 17, 2012Assignee: GTx, Inc.Inventors: James T. Dalton, Christina Barrett, Yali He, Seoung-Soo Hong, Duane D. Miller, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
-
Patent number: 8003689Abstract: This invention provides metabolites of SARM compounds including inter alia glucuronidated metabolites and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, muscle wasting disease and/or disorder, a bone related disease and/or disorder, metabolic syndrome, diabetes and associated diseases, and others.Type: GrantFiled: June 19, 2009Date of Patent: August 23, 2011Assignee: GTx, Inc.Inventor: Karen A. Veverka
-
Patent number: 7595402Abstract: The present invention provides prodrugs of selective androgen receptor modulators (SARMs), and their use in treating or reducing the incidence of osteoporosis, a variety of hormone-related conditions, conditions associated with Androgen Decline in Aging Male (ADAM); conditions associated with Androgen Decline in Female (ADIF), and muscular wasting conditions, obesity, dry eye conditions, and prostate cancer. The prodrugs are also useful in oral androgen replacement therapy and male contraception.Type: GrantFiled: December 16, 2004Date of Patent: September 29, 2009Assignee: GTx, Inc.Inventors: Duane D. Miller, Mitchell S. Steiner, Karen A. Veverka, James T. Dalton
-
Patent number: 7524866Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.Type: GrantFiled: February 17, 2004Date of Patent: April 28, 2009Assignee: GTx, Inc.Inventors: Mitchell S. Steiner, Sharan Raghow, Karen A. Veverka
-
Patent number: D668186Type: GrantFiled: March 31, 2011Date of Patent: October 2, 2012Assignee: Usine GTX, Inc.Inventor: Gabriel Tremblay